1. Home
  2. BGLC vs OGEN Comparison

BGLC vs OGEN Comparison

Compare BGLC & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

N/A

Current Price

$2.07

Market Cap

5.0M

Sector

Health Care

ML Signal

N/A

Logo Oragenics Inc.

OGEN

Oragenics Inc.

HOLD

Current Price

$0.59

Market Cap

2.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGLC
OGEN
Founded
2017
1996
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0M
2.7M
IPO Year
2019
2010

Fundamental Metrics

Financial Performance
Metric
BGLC
OGEN
Price
$2.07
$0.59
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.0K
40.1K
Earning Date
04-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
45.78
N/A
EPS
N/A
N/A
Revenue
$7,424,911.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.92
$0.11
52 Week High
$15.19
$9.16

Technical Indicators

Market Signals
Indicator
BGLC
OGEN
Relative Strength Index (RSI) 47.20 46.59
Support Level $1.92 $0.56
Resistance Level $2.15 $0.66
Average True Range (ATR) 0.07 0.04
MACD 0.02 0.00
Stochastic Oscillator 70.00 41.71

Price Performance

Historical Comparison
BGLC
OGEN

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.

About OGEN Oragenics Inc.

Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.

Share on Social Networks: